Cure My Disease

Don't miss your cure!

 Log in / Sign up

New probe lights up PD-L1 across tumors

NCT ID NCT07848243

Diagnosis Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 29, 2026 · Last updated Sep 30, 2026 · Updated 1 time

Summary

Researchers are testing a radionuclide probe that targets PD-L1, a protein some tumors use to evade the immune system. Adults with solid tumors such as lung, cervical, breast, melanoma, or gastrointestinal cancers receive the probe and then undergo whole-body PET/CT imaging. The trial checks whether the imaging is safe and produces usable pictures, and whether it can reveal differences in PD-L1 levels between tumors and over time. The goal is to see if this approach could one day help doctors pick patients for targeted therapy and monitor for resistance or recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a PD-L1-targeted radionuclide imaging probe
What this could lead to
If it works, doctors could use PET/CT imaging to see PD-L1 levels across a patient's tumors and track how they change, which may help select who benefits from immunotherapy and flag early resistance or recurrence.
What could go wrong
This is a small Phase 2 imaging study, so it may not show that the probe reliably measures PD-L1 or predicts treatment response. The tracer could cause side effects, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>18 years old, ECOG score 0 or 1; 2. subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors; 3. There was at least one measurable target lesion according to RECIST1.1 criteria; 4. Predicted survival time ≥12 weeks; 5. Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements; 6. Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period; 7. Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good. Exclusion Criteria: 1. Severe abnormal liver and kidney function. 2. Pre-pregnancy, pregnant and lactating women. 3. Unable to lie flat for half an hour. 4. Refusal to be a clinical investigator. 5. Claustrophobia or other mental illness. 6. Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm cervical squamous cell carcinoma digestive system cancer digestive system neoplasm lung cancer lung neoplasm melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Cervical squamous cell cancer Gastrointestinal cancers Lung cancer (NSCLC) Melanoma (skin cancer)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Cancer hospital

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.